Is it true that a large proportion of ovarian cancer actually originates from the fallopian tube (tubal cancer)?

Yes, a significant majority of what we call "ovarian cancer" actually originates from the fallopian tube, specifically high-grade serous carcinoma.

There is compelling evidence that in a significant majority of cases—but possibly not all—the precursors of high-grade serous carcinoma (HGSC) originate in the fallopian tube, particularly at the fimbrial end, rather than the ovary itself 1.

The Evidence Behind This Paradigm Shift

What the Data Shows

The 2015 International Collaboration on Cancer Reporting (ICCR) guidelines document that when fallopian tubes are examined completely:

• 59% of cases show serous tubal intraepithelial carcinomas (STICs)
• An additional 15% show invasive HGSC in the fallopian tube mucosa
• This means 74% of cases have identifiable tubal involvement 1

The 2024 ESGO-ESMO-ESP consensus confirms that most HGSCs develop from STIC at the fimbrial end of the fallopian tube 2. Research data from 2010 found STICs in approximately 59-67% of high-grade serous carcinomas when tubes were completely examined 3.

Critical Nuances to Understand

This applies specifically to high-grade serous carcinoma only—which represents approximately 70% of all ovarian cancers and 90% of advanced-stage cases 1. The other histologic subtypes have different origins:

• Clear cell, endometrioid, low-grade serous, and mucinous carcinomas: Site assignment remains straightforward—these generally do originate from the ovary 1
• Endometrioid and clear cell: Strong link to endometriosis 4
• Low-grade serous: Arise from ovarian cystadenomas/adenofibromas through borderline tumors 5

The Molecular Evidence

The evidence supporting tubal origin is robust:

• STICs harbor identical p53 mutations to extratubal tumors, establishing clonal relationship 1
• Telomere length and centrosome amplification comparisons suggest STICs develop before ovarian tumors 1
• Early incidental HGSCs are predominantly detected in fallopian tube mucosa, especially fimbriae, rather than ovary 1

Clinical Implications

This paradigm shift has transformed practice:

1. Pathology protocols: The SEE-FIM protocol (complete examination of fimbrial ends) is now standard to avoid missing the actual tumor origin 1

2. Site designation: The FIGO 2014 staging system now designates primary site as ovarian, tubal, or primary peritoneal—no longer based on greatest tumor volume but on presence of STIC or invasive HGSC in tubal mucosa 1

3. Prevention strategies: This knowledge supports opportunistic salpingectomy for HGSC prevention in average-risk women 6

4. Cancer registry data: The apparent "increase" in fallopian tube cancer and "decrease" in ovarian cancer over recent years reflects reclassification rather than true epidemiologic change 7

Important Caveats

• Not all HGSCs show identifiable STICs even with complete tubal examination—some cases may have obliterated fimbrial ends or truly different origins 1
• When primary site cannot be determined, cases should be categorized as "undesignated" or "tubo-ovarian HGSC" 1
• The term "ovarian cancer" persists clinically despite being somewhat misleading, as changing terminology would create confusion during transition 4, 8

Bottom line: For HGSC specifically, the statement is largely true—most originate from the fallopian tube. However, "ovarian cancer" as a broad category includes multiple distinct diseases with different origins, and only the high-grade serous subtype predominantly arises from the tube.